AXZ
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Amex Resources Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Amex Resources Limited
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AXZ
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in AXZ
N/A
AXZ investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in AXZ also invest in...
Want more shares? Try these...
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. The company is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The firm has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.
📊 Share price
$0.80 AUD
🩺 HEALTH CARE
